These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 19687324)

  • 1. Second-line chemotherapy for advanced urothelial cancer: because we should or because we can?
    Dreicer R
    J Clin Oncol; 2009 Sep; 27(27):4444-5. PubMed ID: 19687324
    [No Abstract]   [Full Text] [Related]  

  • 2. Novel agents for muscle-invasive and advanced urothelial cancer.
    Sonpavde G; Ross R; Powles T; Sweeney CJ; Hahn N; Hutson TE; Galsky MD; Lerner SP; Sternberg CN
    BJU Int; 2008 Apr; 101(8):937-43. PubMed ID: 18005203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nomogram to predict the benefit from salvage systemic therapy for advanced urothelial carcinoma.
    Sonpavde G; Pond GR; Fougeray R; Bellmunt J
    BJU Int; 2015 Jun; 115(6):854-5. PubMed ID: 25195625
    [No Abstract]   [Full Text] [Related]  

  • 4. Progress in treatment of advanced urothelial tract tumors.
    Yagoda A
    J Clin Oncol; 1985 Nov; 3(11):1448-50. PubMed ID: 3903061
    [No Abstract]   [Full Text] [Related]  

  • 5. Response and Development of Immune-Related Adverse Events in an 83-Year-Old Man With Metastatic Urothelial Cancer.
    Mehra KK; Petrylak DP
    Oncology (Williston Park); 2018 Mar; 32(3):132-6. PubMed ID: 29548069
    [No Abstract]   [Full Text] [Related]  

  • 6. Re: Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.
    Tilgener C; Bedke J
    Eur Urol; 2024 Jun; 85(6):591-592. PubMed ID: 38538421
    [No Abstract]   [Full Text] [Related]  

  • 7. Vinflunine: a new microtubule inhibitor agent.
    Bennouna J; Delord JP; Campone M; Nguyen L
    Clin Cancer Res; 2008 Mar; 14(6):1625-32. PubMed ID: 18347163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current optimal chemotherapy for advanced urothelial cancer.
    Sonpavde G; Galsky MD; Hutson TE
    Expert Rev Anticancer Ther; 2008 Jan; 8(1):51-61. PubMed ID: 18095883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frontiers in combining immune checkpoint inhibitors for advanced urothelial cancer management.
    Rebhan K; Laukhtina E; Shariat SF; Gust KM
    Curr Opin Urol; 2020 May; 30(3):457-466. PubMed ID: 32235284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cochrane Rapid Review: the immune checkpoint inhibitor pembrolizumab versus chemotherapy for the treatment of advanced urothelial carcinoma].
    Wilborn D; Schmidt S
    Urologe A; 2019 Jan; 58(1):45-48. PubMed ID: 30560284
    [No Abstract]   [Full Text] [Related]  

  • 11. Predictive biomarkers for immunotherapy in the treatment of advanced urothelial carcinoma: where we stand and where we go.
    Gevaert T; Cimadamore A; Eckstein M; Scarpelli M; Lopez-Beltran A; Cheng L; Montironi R
    Future Oncol; 2019 Jul; 15(19):2199-2202. PubMed ID: 31213082
    [No Abstract]   [Full Text] [Related]  

  • 12. Promoter hypermethylation: a new therapeutic target emerges in urothelial cancer.
    Cote RJ; Laird PW; Datar RH
    J Clin Oncol; 2005 May; 23(13):2879-81. PubMed ID: 15753457
    [No Abstract]   [Full Text] [Related]  

  • 13. [High response rates for erdafitinib in patients with FGFR-mutated urothelial carcinoma following failure of platinum-based chemotherapy].
    Grülllich C
    Urologe A; 2020 Apr; 59(4):478-479. PubMed ID: 32103289
    [No Abstract]   [Full Text] [Related]  

  • 14. [Chemotherapy indications in the treatment of metastases from urological malignancies].
    Théodore C
    Prog Urol; 2008 Nov; 18 Suppl 7():S219-22. PubMed ID: 19070795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Re: Twardowski et al.: Phase II study of aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer: a California Cancer Consortium Trial (Urology 2010;76:923-926).
    Twardowski P
    Urology; 2012 May; 79(5):1191-2. PubMed ID: 22546405
    [No Abstract]   [Full Text] [Related]  

  • 16. Understanding Adjuvant Therapy for Upper Tract Urothelial Carcinoma.
    Berg SA; Galsky MD
    J Clin Oncol; 2024 May; 42(13):1459-1461. PubMed ID: 38359384
    [No Abstract]   [Full Text] [Related]  

  • 17. Re: Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma.
    Bedke J; Maas M
    Eur Urol; 2021 Aug; 80(2):257-258. PubMed ID: 33895011
    [No Abstract]   [Full Text] [Related]  

  • 18. Re: Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma (the POUT Trial): A Phase 3, Open-label, Randomised Controlled Trial.
    Afferi L; Moschini M; Mattei A; Montorsi F; Briganti A; Cathelineau X; Sanchez-Salas R
    Eur Urol; 2020 Aug; 78(2):289-290. PubMed ID: 32359702
    [No Abstract]   [Full Text] [Related]  

  • 19. Enfortumab Vedotin in Advanced Urothelial Carcinoma.
    Yeon SH; Lee HJ
    N Engl J Med; 2021 Jul; 385(1):93. PubMed ID: 34192440
    [No Abstract]   [Full Text] [Related]  

  • 20. Enfortumab Vedotin in Advanced Urothelial Carcinoma. Reply.
    Petrylak DP; Powles T; Rosenberg JE
    N Engl J Med; 2021 Jul; 385(1):93-94. PubMed ID: 34192441
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.